Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2019
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. The filing text does not provide revenue, profit, cash flow, margins, or debt figures.
- Funds Raised: $1.0 million
- Shares Issued: 606,061 shares of Class A common stock
- Price Per Share: $1.65
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The Company exercised its right under a March 18, 2019 Letter Agreement to require the Investor to purchase additional shares. This transaction increased the Company's cash position by $1.0 million and diluted existing shareholders by the issuance of 606,061 new shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction is qualified by reference to the March 2019 Letter Agreement (Exhibit 10.2). No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the terms of the March 2019 Letter Agreement referenced in Exhibit 10.2 to understand the full scope of the Investor's obligations.
- Confirm the post-transaction share count and dilution impact on existing holdings.
- Review subsequent filings to determine how the $1.0 million infusion was utilized.